Vital Images extends Toshiba agreement
The symbiotic relationship between Vital Images and Toshiba Medical Systems will continue under a U.S. and international marketing and distribution agreement that extends Toshiba's right to offer Vital Images' Vitrea 2 software. Toshiba has distributed
The symbiotic relationship between Vital Images and Toshiba Medical Systems will continue under a U.S. and international marketing and distribution agreement that extends Toshiba's right to offer Vital Images' Vitrea 2 software. Toshiba has distributed the software since 2000 through its subsidiaries and distributors in more than 50 nations in North and South America, Europe, the Middle East, Africa, Australia, and Asia, excluding Japan. The 3D medical imaging product is sold primarily as an adjunct to Toshiba's Aquilion and Asteon CT scanners. The new agreement includes a minimum worldwide revenue commitment from Toshiba of $7.7 million and is effective through Dec. 31, 2004. At the RSNA meeting, Vital Images demonstrated Vitrea version 3.4 offering enhanced 3D visualization and analysis tools, including automated tools for examining vasculature.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
